Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies

References

• Benson RA, Brewer JM, Platt AM. Mechanisms of autoimmunity in human diseases: a critical review of current dogma. Curr Opin Rheumatol. 2014;26:197–203.
   PubMed Web of Science ®Google Scholar
• Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125:2228–2233.
   PubMed Web of Science ®Google Scholar
• Ferri C, Manfredi A, Sebastiani M, et al. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: our interdisciplinary rheumatology-pneumology experience, and review of the literature. Autoimmun Rev. 2016;15:61–70.
   PubMed Web of Science ®Google Scholar
• Reina D, Roig Vilaseca D, Torrente-Segarra V, et al. Sjogren’s syndrome-associated interstitial lung disease: a multicenter study. Reumatol Clin. 2016;12:201–205.
   Google Scholar
• Hu Y, Wang LS, Wei YR, et al. Clinical characteristics of connective tissue disease-associated interstitial lung disease in 1,044 Chinese patients. Chest. 2016;149:201–208.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47:588–596.
   PubMed Web of Science ®Google Scholar
• Demoruelle MK, Mittoo S, Solomon JJ. Connective tissue disease-related interstitial lung disease. Best Pract Res Clin Rheumatol. 2016;30:39–52.
   PubMed Web of Science ®Google Scholar
• Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis. 2015;7:247–267.
   PubMed Web of Science ®Google Scholar
• Oldham JM, Adegunsoye A, Valenzi E, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016;47:1767–1775.
   PubMed Web of Science ®Google Scholar
• Jani M, Hirani N, Matteson EL, et al. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Reviews Rheumatol. 2014;10:284–294.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine. 2007;86:242–251.
   PubMed Web of Science ®Google Scholar
• Sharp C, McCabe M, Dodds N, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology. 2016;55:1318–1324.
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372–378.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583–1591.
   PubMed Web of Science ®Google Scholar
• Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology. 2014;53:1676–1682.
   PubMed Web of Science ®Google Scholar
• Koo BS, Hong S, Kim YJ, et al. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med. 2015;30:104–109.
   PubMed Web of Science ®Google Scholar
• Han Q, Luo Q, Chen X, et al. The evaluation of clinical usefulness of transbrochoscopic lung biopsy in undefined interstitial lung diseases: a retrospective study. Clin Respir J. 2015;DOI:10.1111/crj.12318.
   Google Scholar
• Tan TC, Wienholt L, Adelstein S. TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia. Int J Rheum Dis. 2016;19:996–1001.
   PubMed Web of Science ®Google Scholar
• Cavagna L, Nuno L, Scire CA, et al. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study. Medicine. 2015;94:e1144.
   PubMed Web of Science ®Google Scholar
• Yin Y, Liang D, Zhao L, et al. Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. Plos One. 2014;9:e92449.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Ryu JH, Tazelaar HD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med. 2013;107:1247–1252.
   PubMed Web of Science ®Google Scholar
• Al-Ghamdi A, Attar SM. Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. Ann Saudi Med. 2009;29:189–193.
   PubMed Web of Science ®Google Scholar
• Wang JX, Du CG. A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients. Med Sci Monit. 2015;21:708–715.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Kaneko Y, Yamaoka K, et al. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int. 2016;36:881–889.
   PubMed Web of Science ®Google Scholar
• Chang B, Wigley FM, White B, et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003;30:2398–2405.
   PubMed Web of Science ®Google Scholar
• Launay D, Mouthon L, Hachulla E, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol. 2007;34:1005–1011.
   PubMed Web of Science ®Google Scholar
• Wangkaew S, Euathrongchit J, Wattanawittawas P, et al. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study. Mod Rheumatol. 2016;24:588–593.
   Google Scholar
• Oguz EO, Kucuksahin O, Turgay M, et al. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study. Clin Rheumatol. 2016;35:663–666.
   PubMed Web of Science ®Google Scholar
• Perez-Dorame R, Mejia M, Mateos-Toledo H, et al. Rheumatoid arthritis-associated interstitial lung disease: lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. Reumatol Clin. 2015;11:12–16.
   PubMedGoogle Scholar
• Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014;73:1487–1494.
   PubMed Web of Science ®Google Scholar
• Chen J, Shi Y, Wang X, et al. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol. 2013;2013:406927.
   PubMedGoogle Scholar
• Richman NC, Yazdany J, Graf J, et al. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine. 2013;92:92–97.
   PubMed Web of Science ®Google Scholar
• Zou YQ, Li YS, Ding XN, et al. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatol Int. 2012;32:669–673.
   PubMed Web of Science ®Google Scholar
• Mohd Noor N, Mohd Shahrir MS, Shahid MS, et al. Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease. Int J Rheum Dis. 2009;12:136–144.
   PubMed Web of Science ®Google Scholar
• Zayeni H, Haji-Abbasi A, Foumani SA, et al. Pulmonary involvement in rheumatoid arthritis: a cross-sectional study in Iran. Lung India. 2016;33:49–52.
   PubMed Web of Science ®Google Scholar
• Teh CL, Wong JS. The pattern and clinical manifestations of rheumatoid arthritis in Sarawak General Hospital. Clin Rheumatol. 2008;27:1437–1440.
   PubMed Web of Science ®Google Scholar
• Bharadwaj A, Haroon N. Interstitial lung disease and neuropathy as predominant extra-articular manifestations in patients with rheumatoid arthritis: a prospective study. Med Sci Monit. 2005;11:CR498–502.
   PubMed Web of Science ®Google Scholar
• Zrour SH, Touzi M, Bejia I, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. Joint Bone Spine. 2005;72:41–47.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69:1086–1091.
   PubMed Web of Science ®Google Scholar
• Hadjinicolaou AV, Nisar MK, Bhagat S, et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases–a systematic literature review. Rheumatology. 2011;50:2297–2305.
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41:256–264.
   PubMed Web of Science ®Google Scholar
• Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43:613–626.
   PubMed Web of Science ®Google Scholar
• Taki H, Kawagishi Y, Shinoda K, et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int. 2009;30:275–276.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30:S17–22.
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol. 2012;2012:946048.
   PubMedGoogle Scholar
• Yoo WH. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int. 2012;32:795–798.
   PubMed Web of Science ®Google Scholar
• Yasuoka H. Recent treatments of interstitial lung disease with systemic sclerosis. Clin Med Insights Circ Respir Pulm Med. 2015;9:97–110.
   PubMedGoogle Scholar
• Chartrand S, Swigris JJ, Peykova L, et al. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2016;32:296–304.
   PubMed Web of Science ®Google Scholar
• Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess (Rockv). 2016;20:1–610.
   Web of Science ®Google Scholar
• Hasegawa M, Takehara K. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Semin Arthritis Rheum. 2012;42:281–296.
   PubMed Web of Science ®Google Scholar
• Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol. 2011;25:549–567.
   PubMed Web of Science ®Google Scholar
• Guerra I, Perez-Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22:894–901.
   PubMed Web of Science ®Google Scholar
• Komaki Y, Komaki F, Sakuraba A, et al. Approach to optimize anti-TNF-alpha therapy in patients with IBD. Curr Treat Options Gastroenterol. 2016;14:83–90.
   PubMedGoogle Scholar
• Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. Plos One. 2012;7:e30275.
   PubMed Web of Science ®Google Scholar
• Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum. 2006;54:635–641.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Alten R, Van Den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46:1470–1479.
   PubMed Web of Science ®Google Scholar
• Hui-Yuen JS, Li XQ, Askanase AD. Belimumab in systemic lupus erythematosus: a perspective review. Ther Adv Musculoskelet Dis. 2015;7:115–121.
   PubMed Web of Science ®Google Scholar
• Keidel SM, Hoyles RK, Wilkinson NM. Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra. Rheumatology. 2014;53:573–574.
   PubMed Web of Science ®Google Scholar
• Mohr M, Jacobi AM. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol. 2011;40:400–401.
   PubMed Web of Science ®Google Scholar
• Ostendorf B, Iking-Konert C, Kurz K, et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64:630–633.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J. 2004;24:708.
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol. 2007;25:23–28.
   PubMed Web of Science ®Google Scholar
• Horai Y, Miyamura T, Shimada K, et al. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther. 2012;37:117–121.
   PubMed Web of Science ®Google Scholar
• Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest. 2002;122:1093–1096.
   PubMedGoogle Scholar
• Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188–1194.
   PubMed Web of Science ®Google Scholar
• Kabia A, Md Yusof MY, Dass S, et al. Efficacy and safety of rituximab in rheumatoid arthritis patients with concomitant interstitial lung disease: 10-year experience at single centre. Rheumatology. 2015;54:i86.
   Web of Science ®Google Scholar
• Wallace B, Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol. 2016;28:236–245.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu SQ, Xu JH, et al. Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease. Clin Med Insights Case Rep. 2011;4:49–52.
   PubMedGoogle Scholar
• Hartung W, Maier J, Pfeifer M, et al. Effective treatment of rheumatoid arthritis-associated interstitial lung disease by B-cell targeted therapy with rituximab. Case Rep. 2012;2012:272303.
   Google Scholar
• Braun-Moscovici Y, Markovits D, Rozin A, et al. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J. 2008;10:277–281.
   PubMed Web of Science ®Google Scholar
• Fitzgerald DB, Moloney F, Twomey M, et al. Efficacy and safety of rituximab in connective tissue disease related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:215–221.
   PubMed Web of Science ®Google Scholar
• Lam GK, Hummers LK, Woods A, et al. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol. 2007;34:1636–1637.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49:271–280.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology. 2008;47:552–553.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC, et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum. 2010;40:127–136.
   PubMed Web of Science ®Google Scholar
• Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72:1217–1220.
   PubMed Web of Science ®Google Scholar
• Becker MO, Bruckner C, Scherer HU, et al. The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis. 2011;70:1340–1341.
   PubMed Web of Science ®Google Scholar
• Sumida H, Asano Y, Tamaki Z, et al. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol. 2014;41:418–420.
   PubMed Web of Science ®Google Scholar
• Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44:428–436.
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630–2640.
   PubMed Web of Science ®Google Scholar
• Park JK, Yoo HG, Ahn DS, et al. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int. 2012;32:3587–3590.
   PubMed Web of Science ®Google Scholar
• Marie I, Dominique S, Janvresse A, et al. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106:581–587.
   PubMed Web of Science ®Google Scholar
• Olivas-Flores EM, Bonilla-Lara D, Gamez-Nava JI, et al. Interstitial lung disease in rheumatoid arthritis: current concepts in pathogenesis, diagnosis and therapeutics. World J Rheumatol. 2015;5:1–22.
   Google Scholar
• Komiya K, Ishii H, Fujita N, et al. Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement. Intern Medicine. 2011;50:749–751.
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Studler U, Tamm M, et al. Long-term treatment with infliximab in patients with sarcoidosis. Respiration. 2012;83:218–224.
   PubMed Web of Science ®Google Scholar
• Dass S, Atzeni F, Vital E, et al. Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease. Ann Rheum Dis. 2011;70:71.
   Web of Science ®Google Scholar
• Becerra G, Cambridge M. Safety and efficacy of rituximab in patients with rheumatoid arthritis and lung involvement. Ann Rheum Dis. 2013;72:450.
   Google Scholar
• Romero FI, Recuero S, Gόmez-Seco J, et al. AB0800 Safety and clinical response to rituximab in patients with connective tissue disease-associated interstitial lung disease: preliminary results. Ann Rheum Dis. 2013;71:684.
   Google Scholar
• Haroon M, McLaughlin P, Henry M, et al. Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis. 2011;5:299–304.
   PubMedGoogle Scholar
• Matteson EL, Dellaripa PF, Ryu JH, et al. Open-label pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Arthritis Rheum. 2011;63:2212.
   Google Scholar
• Yunt ZX, Solomon JJ. Lung disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2015;41:225–236.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, et al. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med. 2011;124:386–394.
   PubMed Web of Science ®Google Scholar
• Cairns AP, Taggart AJ. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J. 2002;71:101–105.
   PubMedGoogle Scholar
• Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet. 1999;354:1932–1939.
   PubMed Web of Science ®Google Scholar
• Garcia-Vicuña R, Ortiz AM, Carmona L, et al. Inflammatory interstitial lung disease in rheumatoid arthritis patients treated with biologic treatment. Incidence and mortality rates compared with patients non receiving biologics. Ann Rheum Dis. 2005;64(Suppl. 3):470.
   Google Scholar
• Ryan JG, Murphy E, Barry M. Biologic therapy: a countrywide survey of anti-TNF use and associated complications. Ann Rheum Dis. 2006;65(Suppl. 2):499.
   Google Scholar
• Panopoulos ST, Sfikakis PP Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med. 2011;17:362–367.
   PubMed Web of Science ®Google Scholar
• Nakashita T, Ando K, Kaneko N, et al. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4:e005615.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–194.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatology /The Japan Rheum Assoc. 2011;21:343–351.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatology /The Japan Rheum Assoc. 2012;22:498–508.
   PubMed Web of Science ®Google Scholar
• Kramer N, Chuzhin Y, Kaufman LD, et al. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2002;47:670–671.
   PubMed Web of Science ®Google Scholar
• Courtney PA, Alderdice J, Whitehead EM Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2003;49:617. author reply −8.
   PubMed Web of Science ®Google Scholar
• Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol. 2004;33:276–277.
   PubMed Web of Science ®Google Scholar
• Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006;33:1189–1193.
   PubMed Web of Science ®Google Scholar
• Mori S, Imamura F, Kiyofuji C, et al. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatology /The Japan Rheum Assoc. 2006;16:251–255.
   PubMedGoogle Scholar
• Ostor AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33:622–628.
   PubMed Web of Science ®Google Scholar
• Ostor AJ, Crisp AJ, Somerville MF, et al. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. Bmj. 2004;329:1266.
   PubMed Web of Science ®Google Scholar
• Hennum J, Nace J, Shammash E, et al. Infliximab-associated pneumonitis in rheumatoid arthritis. J Rheumatol. 2006;33:1917–1918.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Isogai S, Sakurai T, et al. A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis. Mod Rheumatology /The Japan Rheum Assoc. 2010;20:518–521.
   PubMed Web of Science ®Google Scholar
• Schoe A, Van Der Laan-Baalbergen NE, Huizinga TW, et al. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum. 2006;55:157–159.
   PubMed Web of Science ®Google Scholar
• Dascalu C, Mrejen-Shakin K, Bandagi S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J Clin Rheumatol. 2010;16:172–174.
   PubMed Web of Science ®Google Scholar
• Dias OM, Pereira DA, Baldi BG, et al. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. J Bras Pneumol. 2014;40:77–81.
   PubMed Web of Science ®Google Scholar
• Lindsay K, Melsom R, Jacob BK, et al. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology. 2006;45:1048–1049.
   PubMed Web of Science ®Google Scholar
• Cho SK, Oh IH, Park CK, et al. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Rheumatol Int. 2012;32:1055–1057.
   PubMed Web of Science ®Google Scholar
• Quintos-Macasa AM, Quinet R. Enbrel-induced interstitial lung disease. South Med J. 2006;99:783–784.
   PubMed Web of Science ®Google Scholar
• Tournadre A, Ledoux-Eberst J, Poujol D, et al. Exacerbation of interstitial lung disease during etanercept therapy: two cases. Joint Bone Spine. 2008;75:215–218.
   PubMed Web of Science ®Google Scholar
• Hagiwara K, Sato T, Takagi-Kobayashi S, et al. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34:1151–1154.
   PubMed Web of Science ®Google Scholar
• Sakaida H, Komase Y, Takemura T. Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept. Mod Rheumatology /The Japan Rheum Assoc. 2010;20:611–616.
   PubMed Web of Science ®Google Scholar
• Glaspole IN, Hoy RF, Ryan PF A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology. 2013;52:2302–2304.
   PubMed Web of Science ®Google Scholar
• Lager J, Hilberg O, Lokke A, et al. Severe interstitial lung disease following treatment with certolizumab pegol: a case report. Eur Respir Rev. 2013;22:414–416.
   PubMedGoogle Scholar
• Millar A, McKew J, Taggart A. Fatal fibrosing alveolitis with certolizumab. Rheumatology. 2012;51:953–955.
   PubMed Web of Science ®Google Scholar
• Migita K, Tsuji Y, Hisatomi K, et al. Acute exacerbation of rheumatoid interstitial lung disease during the maintenance therapy with certolizumab pegol. Mod Rheumatol. 2016;DOI:10.3109/14397595.2015.1059008.
   Google Scholar
• Pearce F, Johnson SR, Courtney P. Interstitial lung disease following certolizumab pegol. Rheumatology. 2012;51:578–580.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–997.
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Kawakami A, Sakamoto N, et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int. 2012;32:4023–4026.
   PubMed Web of Science ®Google Scholar
• Wendling D, Vidon C, Godfrin-Valnet M, et al. Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine. 2013;80:670–671.
   PubMed Web of Science ®Google Scholar
• Wada T, Akiyama Y, Yokota K, et al. [A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept]. Nihon Rinsho Meneki Gakkai Kaishi. 2012;35:433–438.
   PubMedGoogle Scholar
• Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology. 2012;51:653–662.
   PubMed Web of Science ®Google Scholar
• Kishi J, Nanki T, Watanabe K, et al. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology. 2009;48:447–448.
   PubMed Web of Science ®Google Scholar
• Piazza T, Tonin FS, Steimbach LM, et al. Occurrence of treatment interruption during therapy with biological agents in patients with previous anti-TNF failure in rheumatoid arthritis. Value Health. 2015;18:A874.
   PubMedGoogle Scholar
• Ramos-Casals M, Brito-Zeron P, Munoz S, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine. 2008;87:345–364.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatology /The Japan Rheum Assoc. 2014;24:390–398.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study. Rheumatol Int. 2012;32:1617–1624.
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178:948–955.
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889–894.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatology /The Japan Rheum Assoc. 2012;22:327–338.
   PubMed Web of Science ®Google Scholar
• Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1096–1104.
   PubMed Web of Science ®Google Scholar
• Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther. 2008;10:393–406.
   PubMed Web of Science ®Google Scholar
• Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology. 2006;45:1312–1313.
   PubMed Web of Science ®Google Scholar
• Ikegawa K, Hanaoka M, Ushiki A, et al. A case of organizing pneumonia induced by tocilizumab. Intern Medicine. 2011;50:2191–2193.
   PubMed Web of Science ®Google Scholar
• Leon RJ, Gonsalvo A, Salas R, et al. Rituximab-induced acute pulmonary fibrosis. Mayo Clinic Proceedings. 2004;79:949, 53.
   Web of Science ®Google Scholar
• Soubrier M, Jeannin G, Kemeny JL, et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine. 2008;75:362–365.
   PubMed Web of Science ®Google Scholar
• Mori S. Management of rheumatoid arthritis patients with interstitial lung disease: safety of biological antirheumatic drugs and assessment of pulmonary fibrosis. Clin Med Insights Circ Respir Pulm Med. 2015;9:41–49.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013;40:787–797.
   PubMed Web of Science ®Google Scholar
• Tan J, Ni X. TNF-alpha antagonist may not be suitable for severe rituximab-induced interstitial lung disease. J Clin Pharm Ther. 2015;40:249–250.
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Harrold LR, Liu L, et al. Association between anti-TNF-alpha therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013;22:394–402.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Sarsour K, Napalkov P, et al. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319.
   PubMed Web of Science ®Google Scholar
• Furukawa H, Oka S, Shimada K, et al. Genetics of interstitial lung disease: Vol de Nuit (Night Flight). Clin Med Insights Circ Respir Pulm Med. 2015;9:1–7.
   PubMedGoogle Scholar
• Fonseca C, Lindahl GE, Ponticos M, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med. 2007;357:1210–1220.
   PubMed Web of Science ®Google Scholar
• Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol. 2014;26:64–71.
   PubMed Web of Science ®Google Scholar
• Wells AU, Denton CP Interstitial lung disease in connective tissue disease–mechanisms and management. Nat Reviews Rheumatol. 2014;10:728–739.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Khan K, Shiwen X, et al. Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum. 2008;58:1175–1188.
   PubMed Web of Science ®Google Scholar
• Walker N, Badri L, Wettlaufer S, et al. Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts. Am J Pathol. 2011;178:2461–2469.
   PubMed Web of Science ®Google Scholar
• Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009;36:773–780.
   PubMed Web of Science ®Google Scholar
• Bartis D, Mise N, Mahida RY, et al. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important? Thorax. 2014;69:760–765.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Nakamura H, Takenouchi K, et al. Serum KL-6 elevation and possible pulmonary involvement in patients with rheumatoid arthritis treated with biological agents. J Nippon Med Sch. 2014;81:364–371.
   PubMed Web of Science ®Google Scholar
• Shaw M, Collins BF, Ho LA, et al. Rheumatoid arthritis-associated lung disease. Eur Respir Rev. 2015;24:1–16.
   PubMedGoogle Scholar
• Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum. 2010;40:147–163.
   PubMed Web of Science ®Google Scholar
• Sharp C, Dodds N, Mayers L, et al. The role of biologics in treatment of connective tissue disease-associated interstitial lung disease. Qjm. 2015;108:683–688.
   PubMed Web of Science ®Google Scholar
• Sullivan DE, Ferris M, Nguyen H, et al. TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J Cell Mol Med. 2009;13:1866–1876.
   PubMed Web of Science ®Google Scholar
• Kuroki M, Noguchi Y, Shimono M, et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunology. 2003;170:567–574.
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest. 1995;96:250–259.
   PubMed Web of Science ®Google Scholar
• Elias JA. Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin-dependent and -independent mechanisms. Am Rev Respir Dis. 1988;138:652–658.
   PubMed Web of Science ®Google Scholar
• Sode J, Vogel U, Bank S, et al. Genetic variations in pattern recognition receptor loci are associated with anti-TNF response in patients with rheumatoid arthritis. Plos One. 2015;10:e0139781.
   Web of Science ®Google Scholar
• Kong H, Wang Y, Zeng X, et al. Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report. J Clin Pharm Ther. 2014;39:691–694.
   PubMed Web of Science ®Google Scholar